This Competitive Intelligence report analyzes the competitive field of WT1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.
The report includes a compilation of currently active projects in research and development of vaccines, TCR-engineered T-cells, Cytotoxic T-Lymphocytes and recombinant antibodies targeting Wilms Tumor 1 (WT1). In addition, the report lists company- and institution-specific R&D pipelines of WT1-Targeted Immunotherapies.
Wilms tumor 1 (WT1) oncoprotein is a zinc finger transcription factor whose expression in normal adult tissue is rare but is overexpressed in leukemias of multiple lineages and a wide range of solid tumors. WT1 expression is a biomarker and a prognostic indicator.
RNA interference knockdown studies of WT1 suggest that it has oncogenic potential and it appears to be expressed in leukemia stem cell populations. A National Institutes of Health-convened panel ranked WT1 as a top cancer target for immunotherapy.
WT1 is a nuclear protein, inaccessible to classical antibody therapy, but vaccine approaches are under way to generate WT1-specific cytotoxic T cell (CTL) responses that recognize peptides presented on the cell surface by MHC class I molecules. Engineering autologous T-cells with a WT1-specific T-cell receptor (TCR) is another approach currently pursued.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- R&D Stage
- Additional comments with a hyperlink leading to the source of information
Key Topics Covered
1. WT1-Targeted Immunotherapy
- Selective WT1-Targeted Vaccines
- WT1-Specific, Multi-Target Vaccines
- WT1-Selective Adoptive Cell Therapy
- WT1-Specific, Multi-Target Adoptive Cell Therapy
- WT1-Targeted Antibodies
2. Corporate & Institutional WT1 Immunotherapy R&D Pipelines
For more information about this report visit https://www.researchandmarkets.com/research/fh877t/2018_competitor?w=4